Loss of consciousness from acute quetiapine overdosage

Journal of Toxicology - Clinical Toxicology

Volumn 36, Issue 6, 1998, Pages 599-602

  Harmon, Timothy J ^a   Benitez, John G ^a   Krenzelok, Edward P ^a   Cortes Belen, Ernesto ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; METOPROLOL; NALOXONE; QUETIAPINE; SEROTONIN 2 RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOSE TIME EFFECT RELATION; DRUG OVERDOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA; SELF POISONING; SINUS TACHYCARDIA; UNCONSCIOUSNESS;

EID: 0031656218     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.3109/15563659809028056     Document Type: Article

References (16)

1. Tarsy D. Neuroleptic-induced extrapyramidal reactions: Classification, description and diagnosis. Clin Neuropharmacol 1983;6:S9-S26.
2. 1 values. J Pharmacol Exp Ther 1989;25:238-246.
3. Anon: Seroquel: A putative atypical antipsychotic drug with serotonin-and dopamine-receptor antagonist properties: preclinical and early clinical trials in schizophrenia. J Clin Psychiatry 1995;56:438-445.
4. Casey D. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99: S47-S53.
5. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook A, Tuason V, Klerman G. The risks and benefits of clozapine vs chlorpromazine. J Clin Psychopharmacol 1987;7:377-384.
6. Shopsin B, Klein H, Aaronson M, Collora M. Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, double-blind comparison. Arch Gen Psychiatry 1979;36:657-664.
7. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16: 158-169.
8. Saller CF, Salama AI. Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:285-292.
9. Griffith RW, Saameli K. Clozapine and agranulocytosis. Lancet 1975;2:657.
10. Grohmann R, Ruther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology 1989;99:S101-S104.
11. Seroquel. Product Information: Zeneca Pharmaceuticals 1997.
12. Goldstein JM, Litwin LC, Sutton EB, Malick JB. Seroquel: Electrophysical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112: 293-298.
13. Richelson E. Preclinical pharmacology of neuroleptics. Focus on new generation compounds. J Clin Psychiatry 1996;57(suppl 11):4-11.
14. Mady S, Wax P, Wang D, et al. Pediatric clozapine intoxication. Am J Emerg Med 1996;14:462-463.
15. Fabre LF Jr, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: Early indication of safety and efficay in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-378.
16. Ereshefsky L. Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 1996;57(suppl 11):12-25.